Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 162

Results For "NAL"

6624 News Found

Revvity launches reagent technology for targeted therapeutics
News | August 06, 2025

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research


Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
News | August 06, 2025

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter


Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
News | August 06, 2025

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter


Athena Diagnostics enhances Ataxia testing with long-read gene sequencing
Clinical Trials | August 06, 2025

Athena Diagnostics enhances Ataxia testing with long-read gene sequencing

Athena is also exploring the use of this technology for expanded carrier screening


Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
News | August 06, 2025

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine


Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru
Healthcare | August 05, 2025

Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru

This will be Aster’s fifth hospital in Bengaluru


Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
News | August 05, 2025

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore


Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives
Digitisation | August 05, 2025

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery


Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
News | August 05, 2025

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase